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ABSTRACT
Objective: To study the evolution of the neuropathy and long-term disability in a large cohort of
patients with POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin
changes) syndrome following autologous stem cell transplantation (ASCT).
Methods: Retrospective chart review documenting the clinical, electrophysiologic, and laboratory
characteristics of patients with POEMS syndrome undergoing ASCT at Mayo Clinic, Rochester.
Results: Sixty patients with a median follow-up time of 61 months were studied. All patients had
peripheral polyneuropathy and demonstrated neurologic improvement after ASCT (apart from
one patient who died early). Before ASCT, 27 patients (45%) required a wheelchair and 17
(29%) required a walker or foot brace. At the end of the follow-up period, no patient was using
a wheelchair and 23 patients (38%) were using a foot brace. The median Neuropathy Impairment
Score improved from 66 to 48 points at 12 months and to 30 points at most recent follow-up
(p , 0.0001). Median Rankin Scale score improved from 3 to 1.5 (p , 0.0001). Vascular endo-
thelial growth factor levels decreased from a median of 452 to 63.5 pg/mL (p , 0.0001). The
ulnar compound motor action potential amplitude (median) improved from 4.3 to 7.6 mV (p ,
0.0001) and ulnar compound motor action potential conduction velocity (median) improved from
34 to 51 m/s (p , 0.0001). Predicted forced vital capacity improved from 81% to 88% (p ,
0.0001). Periengraftment syndrome occurred in 24 patients. Fourteen patients required addi-
tional chemotherapy and/or radiation following ASCT, but there was no clinical deterioration in
the neuropathy in any of these patients. Six patients died: 1 due to POEMS, 1 due to failed
engraftment, and 4 due to other malignancies (2 myelodysplastic syndrome, 1 lymphoma, 1 met-
astatic lung cancer).
Conclusion: Patients with POEMS syndrome who undergo ASCT have a significant and meaning-
ful improvement of their neuropathy by multiple measurements during both short and long-term
follow-up, which corresponds to reduction in morbidity and disability (none are in wheelchair
long-term). Periengraftment syndrome was common but manageable. Fatal complications,
although rare, did occur, usually in association with other malignancies.
Classification of evidence: This study provides Class IV evidence that for patients with POEMS
syndrome, ASCT improves neuropathy-related function. Neurology® 2015;84:1981–1987
GLOSSARY
ASCT 5 autologous stem cell transplantation; CMAP 5 compound motor action potential; FVC 5 forced vital capacity;
mRS 5 modified Rankin Scale; NCS 5 nerve conduction study; NIS 5 Neuropathy Impairment Score; POEMS 5 polyneu-
ropathy, organomegaly, endocrinopathy, M protein, and skin changes; VEGF 5 vascular endothelial growth factor.
In patients with POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin
changes) syndrome, clinical and neurologic improvement with immunosuppressive medications
or radiation therapy remains low (,50%) and alternative treatments are needed.1,2 Autologous
stem cell transplantation (ASCT) seems to be a more promising treatment strategy.3 Although
randomized controlled trials are not available, experts seem to agree that currently, the preferred
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treatment for POEMS syndrome is ASCT.4,5
This reasoning is based in part on the efficacy
of ASCT in multiple myeloma.
Our group has recently published the long-
term outcomes after ASCT in 59 patients with
POEMS syndrome.3 The report focused on
the hematologic, radiographic, and general
clinical response to ASCT. It did not assess
the details of the polyneuropathy. Further-
more, a review of the neurology literature re-
veals very limited information regarding the
evolution of the neuropathy in patients with
POEMS syndrome in general, and more spe-
cifically following ASCT. To date, the largest
study on the subject included 9 patients with
POEMS treated with ASCT who were pro-
spectively followed over a median of 20
months.6 The results were very promising,
showing neurologic improvements on all
measures. The authors concluded that ASCT
could be considered as a first-line treatment for
appropriate candidates. An editorial accompa-
nying the article praised the encouraging
results but had reservation because of the small
number of patients.7
We hence sought to evaluate the evolution
of the neuropathy and long-term disability of a
large cohort of patients undergoing ASCT at a
single institution.
METHODS Standard protocol approvals, registrations,
and patient consents. The Mayo Clinic institutional review
board approved the study. We queried our bone marrow trans-
plantation database to identify the 61 patients with POEMS syn-
drome who underwent high-dose chemotherapy followed by
ASCT at the Mayo Clinic (Rochester, MN) between March
1999 and June 2012. Information was abstracted from medical
records of patients who had given consent, allowing their
medical records to be used for research purposes.
All patients were seen by neurologists and had detailed
neurologic examination. Other patients with POEMS who did
not undergo ASCT were excluded. Those patients either had radi-
ation for localized disease, i.e., 1 to 3 plasmacytomas, or other
therapies because of perceived ASCT ineligibility (i.e., no active
disease at the time of evaluation, age 70 years, coexisting solid
cancers, and severe dysfunction of single or multiple organ
systems).
Hematologic details. Transplantation details and definitions for
response and relapse were previously defined.3 In general, peripheral
blood stem cells were collected using either cyclophosphamide with
growth factors, growth factors alone, or growth factors with plerix-
afor mobilizing agents. Details of patient conditioning before
ASCT can be found in the prior published study.3 All patients were
conditioned with high-dose melphalan. Posttransplantation-
associated periengraftment syndrome was defined based on the
modified Spitzer criteria, as follows:
• Major criteria: a temperature of 38.3°C without an identi-
fiable infectious etiology, rash involving 25% body surface
area, and noncardiogenic pulmonary edema.
• Minor criteria: bilirubin greater than twice normal, dou-
bling of transaminases, weight gain 2.5% of baseline, or
transient encephalopathy.
Periengraftment syndrome was defined as the presence of all 3
major criteria or 1 major and 2 minor criteria. The requirement
for a neutrophil count of 0.5 3 106/cubic mL around 96 hours
of the criteria was relaxed.3
Data collection. Patients’ demographics and neuropathy char-
acteristics were collected. Neuropathy Impairment Score (NIS),
modified Rankin Scale (mRS) score, vascular endothelial
growth factor (VEGF), nerve conduction study (NCS), forced
vital capacity (FVC), and maximal inspiratory and expiratory
pressure were collected at t0, t1, and t2. T0 was defined as the
time of testing before ASCT, t1 as the time of the first visit after
ASCT, and t2 as the time of the last visit after ASCT. Prior
chemotherapy 6 radiation therapy, organomegaly (hepatomeg-
aly or splenomegaly), endocrinopathies, skin changes, fluid
extravasation, M protein, thrombocytosis, CNS involvement,
and engraftment syndrome were also recorded.
Neuropathy and disability evaluation. The NIS was calcu-
lated from the Mayo Clinic standard neurologic examination
sheet. In brief, the NIS is a summed score of a standard and rep-
resentative list of motor, sensory, and muscle stretch reflex im-
pairments. Scores range from 0 (normal) to 4 (paralyzed) for
motor, and 0 to 2 (absent) for sensation and reflexes, for individ-
ual attributes.8 The higher the NIS, the worse the neuropathy.
For example, a NIS of 188 meant the worst score possible with
complete paralysis and loss of sensation and reflexes in all 4 limbs
with facial and respiratory involvements. We recorded the NIS
prior at t0, t1, and t2. We recorded the mRS score from the
history and correspondence with patients. The mRS measures
the degree of disability in daily living. The score ranges from 0
(no symptoms) to 6 (dead); 1 5 some symptoms without disa-
bility; 2 5 slight disability with inability to perform all previous
activities; 3 5 moderate disability requiring some help, but able
to walk unassisted; 45moderately severe disability with inability
to walk unassisted; and 5 5 severe disability with need for con-
stant nursing care and attention and bedridden. Because the mRS
can be obtained without a detailed neurologic assessment, i.e., the
patient not necessarily evaluated by a neurologist, these scores
were available at a longer follow-up time than the NIS. We also
reviewed the NCS and EMG. Compound motor action
potentials (CMAPs) obtained from tibial nerve stimulation
recording from the adductor hallucis, the fibular nerve
stimulation recording from the extensor digitorum brevis,
median nerve stimulation recording from the abductor pollicis
brevis, and ulnar nerve stimulation recording from the adductor
digiti minimi were noted at t0, t1, and t2. The ulnar CMAP was
chosen for analysis because the median CMAP was not
consistently recorded and the fibular and tibial CMAPs
were frequently absent, even following treatment. The
polyneuropathy was classified as demyelinating according to the
American Academy of Neurology research criteria,9 as mixed
when there was both demyelination and axonal loss, or as
predominately axonal. Autonomic reflex studies were available
on a subset of patients and were often not repeated following
treatment.
Statistical analysis. Descriptive summaries were presented as
frequencies and percentages for categorical variables and median
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and ranges for continuous variables. Data for outcomes of interest
were displayed using side-by-side box plots and/or scatterplots.
Associations between continuous outcomes were assessed using
Pearson correlation coefficient. Kruskal–Wallis test or Wilcoxon
rank sum test was used to compare distribution of continuous
outcomes (i.e., NIS at various time points) across categorical
variables such as type of bone lesion and NIS or number of
features, etc. All of the tests were 2-sided and p values ,0.05
were considered statistically significant. All analyses were
performed using SAS version 9.3 (SAS Inc., Cary, NC).
Research question. The primary research question concerns the
qualitative evaluation of the short- and long-term treatment
response of neuropathy-related function following ASCT in
patients with POEMS syndrome. In this design, this will result
in Level IV evidence.
RESULTS Sixty-one patients with POEMS syn-
drome were identified as having undergone ASCT.
One patient who did not have a formal neurologic
assessment by a neurologist was excluded. Therefore,
60 patients were included in the analysis. Hemato-
logic but not neurologic outcome has been previously
reported in 58 of these patients.3
Baseline characteristics. Baseline characteristics are
summarized in table 1. In 7 patients (12%), no mon-
oclonal protein was detected on serum protein elec-
trophoresis or serum or urine immunofixation (table
1). Six of those 7 patients had prior chemotherapy. Of
those 7 patients, 3 had free light chain in the serum.
The remaining 4 patients’ light chain was determined
on bone marrow biopsy. Neuropathy characteristics
are summarized in table 2. Twenty-seven patients
(45%) were using a wheelchair, 10 patients (17%)
were using a walker, and 7 patients (12%) were
using ankle foot orthoses. The severity of the
neuropathy was independent of the use of prior
radiation or chemotherapy (p 5 0.1), the number
of bone lesions (p 5 0.6), bone lesion type (p 5
0.6), the number of organs involved (features of
POEMS) (p 5 0.06), or VEGF level (figure e-1 on
the Neurology® Web site at Neurology.org).
Fifty-eight patients underwent NCS and EMG
(table 2). Those studies demonstrated sensory and
motor involvement in 55 patients (95%). There were
demyelinating changes in 51 patients (88%). Only 2
patients (3%) had autonomic symptoms (excluding
erectile dysfunction). However, subclinical auto-
nomic abnormalities were found in 11 of the 20 pa-
tients (55%) tested (mild to moderate abnormalities
as follow: 9 patients had impaired cardiovagal func-
tion, 4 had impaired postganglionic cholinergic sudo-
motor function, and 4 had impaired cardioadrenergic
function).
The cohort demonstrated marked disability. At t0,
27 patients (45%) were using a wheelchair (mRS
score 4), 24 patients (40%) had an mRS score of 3,
7 patients (12%) had an mRS score of 2, and only
2 patients (3%) had an mRS score of 1. Eight patients
Table 1 Patient demographics at baseline (t0)
Patients 60 (100)
Median age at ASCT, y (range) 50 (20–69)
Men 38 (63)
Time from diagnosis
to ASCT, mo (range)
4.9 (2.4–261)





Extravascular fluid overload 54 (90)
Skin changes 55 (92)
M protein on immunofixation 53 (88)
Bone lesion 52 (87)
Thrombocytosis 38 (63)
Castleman disease 11 (18)
Papilledema 6 (10)
Monoclonal protein subtype
Serum M protein 53 (88)
IgG 19 (32)
IgM 2 (3)
IgA 1 IgM 1 (2)
Lambda 57 (95)
Kappa 2 (3)
Abbreviations: ASCT 5 autologous stem cell transplanta-
tion; Ig 5 immunoglobulin; XRT 5 radiation therapy.
Data are n (%) unless otherwise indicated.
Table 2 Neuropathy characteristics
Neuropathy characteristics No. (%)
Symptoms
Negative sensory symptoms 48 (80)
Positive sensory symptoms 45 (75)
Neuropathic pain necessitating medications 39 (65)
Opioids 21 (35)
Weakness 53 (88)
Wheelchair, mRS score 4 27 (45)
Electrodiagnostic findings
Sensorimotor neuropathy 55 (95)
Pure motor 3 (5)
Mixed axonal and demyelinating 38 (63)
Demyelinating 13 (22)
Axonal 7 (12)
Abbreviation: mRS 5 modified Rankin Scale.
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had a prior stroke. Six patients had papilledema.
Six patients had headache; 2 of those had a lumbar
puncture with elevated opening pressure (26 and
43 cm Hg, respectively).
Outcomes. Follow-up was available on all 60 patients.
Median final follow-up after ASCT was 61 months
(range 4–162 months). The median follow-up at t1
was 12 months (range 0–40 months) for both NIS
and mRS. The median follow-up time at t2 for most
recent NIS was 49 months (range 3–127 months)
and the median follow-up time at t2 for most
recent mRS was 61 months (range 9–162 months).
The disability in all but one patient improved after
treatment (figures 1 and 2). In the only patient who
did not improve, the worsening of his NIS and mRS
was related to a complicated posttransplant course,
with sepsis necessitating intensive care unit admission.
That patient died at 4 months posttransplant. After
ASCT, there was a marked improvement in NIS
score at first visit (t1) followed by a further
improvement in NIS score at last visit (t2) (median
49 months) (figure 1). NIS improved from 66 points
at t0 to 48 points at t1 and 30 points at t2 (p ,
0.0001). There was significant correlation between the
improvement in NIS scores and level of VEGF at t1
(p, 0.0001). The mRS score decreased from 3.0 at t0
to 2.0 at t1 (p, 0.0001) and from 2.0 to 1.5 at t2 (p5
0.25) (figure 2). At the end of the follow-up, no patient
was using a wheelchair, 3 patients (5%) were using a
walker, 7 patients (12%) were using a cane or crutch,
and 23 patients (38%) were using ankle foot orthoses.
There was no correlation between the duration of
the disease before ASCT and the severity of the neu-
ropathy or the response to treatment. However, when
patients with a lag of more than 2 years to ASCT were
excluded, there was positive correlation between time
to treatment and neuropathy severity (NIS score) at
baseline (Pearson correlation coefficients 0.32) as well
as a negative correlation between time to treatment
and neuropathy improvement (NIS score) following
treatment (Pearson correlation coefficients 20.4
and 20.24 at t1 and t2, respectively). There was no
difference in outcome between patients with predom-
inantly axonal vs those with predominantly demye-
linating neuropathy (p 5 0.2), although the number
of primarily axonal neuropathies was small (n 5 7)
and so power may be insufficient to see a difference.
Disease duration was similar in patients with predom-
inantly axonal vs those with predominantly demye-
linating neuropathy (p 5 0.5).
FVC increased from 81% of predicted value to
88% of predicted value (p , 0.0001) at t1 (median
12 months). Mean inspiratory pressure increased
from 71 to 90 (p , 0.0001) and mean expiratory
pressure increased from 59 to 72 (p5 0.004). VEGF
levels decreased from a median of 452 pg/mL at t0 to
52 pg/mL at t1 (p , 0.0001) and from 74 to
63.5 pg/mL at t2 (p 5 0.45) (figure e-2). Median
ulnar CMAP amplitude improved from 4.3 mV at t0
to 6.5 mV at t1 (p, 0.0001) and from 6.5 to 7.6 mV
at t2 (p , 0.0001) (figure 3). Median ulnar CMAP
conduction velocity improved from 34 m/s at t0 to 43
m/s at t1 (p, 0.0001) and 51 m/s at t2 (p, 0.0001)
(figure 3). Only one patient had a fibular–extensor
digitorum brevis CMAP that could be recorded and
only 3 patients had a tibial–abductor hallucis CMAP
that could be recorded. After treatment, 5 fibular–
extensor digitorum brevis and 6 tibial–abductor hal-
lucis CMAPs were recordable. These CMAPs were
not included in the statistical analysis because of small
sample size. Autonomic symptoms improved in both
patients at t1.
Figure 1 Improvement in NIS following
autologous stem cell transplantation
Median NIS improved from 66 points at t0 to 48 points at
t1 and 30 points at t2 (p , 0.0001). Box 5 25th and
75th percentiles; bars 5 minimum and maximum values.
NIS 5 Neuropathy Impairment Score.
Figure 2 Improvement in mRS score following
autologous stem cell transplantation
Median mRS score decreased from 3.0 at t0 to 2.0 at t1
(p , 0.0001) and from 2.0 to 1.5 at t2 (p 5 0.25). Box 5
25th and 75th percentiles; bars 5 minimum and maximum
values. mRS 5 modified Rankin Scale.
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Morbidity and mortality. Engraftment syndrome
occurred in 24 patients (40%). Engraftment syn-
drome did not affect the NIS at t0, t1, or t2 (p 5
0.6, 0.8, and 0.6, respectively). Six patients died dur-
ing follow-up. One patient died of recurrent POEMS
syndrome. One patient had graft failure and died
early. The other 4 died of other malignancies
(2 myelodysplastic syndrome, 1 lymphoma, and
1 metastatic lung cancer). All of these patients had
improvement of their neuropathy apart from the one
who died early. Eight other patients had progression
or recurrence of their disease—either biochemical or
radiographic, yet their NIS and mRS score continued
to improve. Some of these patients were observed
without intervention; others had radiation therapy
and/or chemotherapy. These patients are discussed
in detail in the prior report.3
DISCUSSION Before the availability of ASCT, ear-
lier treatments for POEMS syndrome with chemo-
therapy yielded a limited improvement of the
neuropathy with ,50% responding and a high mor-
tality with 30% of patients dying within 5 years.
With ASCT, there is a 5-year overall survival of
94% as well as good response to salvage chemother-
apy in the case of radiologic or VEGF progression.3
Our study provides large-scale confirmation that
ASCT improves the peripheral neuropathy, which is
the major driver of the associated morbidity.
In general, patients with POEMS syndrome pre-
sent with weakness, numbness, tingling, and pain in
the lower extremities secondary to a length-
dependent, typically mixed axonal and demyelinating
polyneuropathy.10 These characteristics can cause fre-
quent misdiagnoses with other demyelinating neu-
ropathies, most frequently chronic inflammatory
demyelinating polyradiculoneuropathy. The delay in
diagnosis, as we have shown here, remains a signifi-
cant issue. When patients with longer than 2 years
between diagnosis and ASCT were excluded, those
with longer times to diagnosis were more severely
affected and response to treatment was less pro-
nounced. Atypical features such as distal more than
proximal lower limb weakness, pain, and dyspnea are
more common in POEMS syndrome and help to
differentiate these patients from those with chronic
inflammatory demyelinating polyradiculoneuropa-
thy. In patients with a demyelinating neuropathy, a
monoclonal protein should be sought because 88%
and 95% of patients with POEMS syndrome have a
monoclonal protein and a lambda light chain, respec-
tively, as shown here. The presence of an elevated
VEGF and other systemic features confirm the diag-
nosis. Note that VEGF can be suppressed by prior
immune treatment (e.g., steroids). Additional testing,
such as screening for endocrinopathies, and skeletal
survey and/or PET scan and eventually tissue analysis
of a sclerotic lesion or bone marrow, confirms the
diagnosis.
In patients with POEMS syndrome treated with
ASCT, neurologic improvements often lag behind
other aspects of the disease such as improved VEGF
levels and extravascular volume overload reductions.
However, we demonstrated here that the neuropathy
and disability continued to improve with time after
ASCT. A major finding of this study is that, while
almost half of the patients needed a wheelchair for
ambulation, within a year following ASCT all but
one were able to walk and at the last follow-up, none
were using a wheelchair. This illustrates the dramatic
response to ASCT in patients with POEMS
syndrome.
In the earlier study, VEGF levels correlated well
with the clinical response.3 In our series, there was
Figure 3 Improvement in ulnar CMAP amplitude and conduction velocity following autologous stem cell
transplantation
(A) Ulnar CMAP amplitude improved from a median of 4.3 mV at t0 to 6.5 mV at t1 and from 6.5 to 7.6 mV at t2
(p , 0.0001). (B) Ulnar CMAP conduction velocity improved from a median of 34 m/s at t0 to 43 m/s at t1 and 51 m/s
at t2 (p , 0.0001). Box 5 25th and 75th percentiles; bars 5 minimum and maximum values. CMAP 5 compound motor
action potential; UCMAP 5 ulnar CMAP; ULNARCV 5 ulnar conduction velocity.
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no correlation between the severity of the neuropathy
and the VEGF level at baseline. However, the drop in
VEGF levels correlated well with the improvement in
neuropathy following ASCT. Of note, although an
increasing VEGF level predicts radiographic progres-
sion as measured by fluorodeoxyglucose avidity on
PET scan,3 patients may be stable neurologically or
continue to improve despite POEMS recurrence.
Respiratory involvement is frequent in patients
with POEMS syndrome.11 Respiratory muscle
weakness and cough portend a poorer prognosis.
Almost half of the patients with POEMS syndrome
studied here had respiratory failure. A novel finding
in our series is the improvement in FVC, maximal
inspiratory pressure, and maximal expiratory pres-
sure with ASCT.
ASCT can be performed safely in patients with
POEMS syndrome. While ASCT was associated with
a high incidence of periengraftment syndrome in this
cohort, this was usually well managed with short-term
steroid treatment. The presence of a periengraftment
syndrome did not seem to affect the overall improve-
ment of the neuropathy and disability. There are case
reports that conditioning with lenalidomide decreases
the rate of engraftment syndrome.12 This is a prom-
ising approach that needs further study. Mortality
related to ASCT was low. Only one patient of 60
died directly as a result of ASCT and chemotherapy.
This mortality rate is similar or even lower than what
is observed in ASCT performed in other malignant
conditions.13 Furthermore, this mortality rate is much
lower than what is observed in patients with POEMS
syndrome treated with steroids and melphalan alone.
The retrospective nature of this study did not
allow comparison of neuropathy outcomes with a
control group receiving a standard alkylator-based
treatment or other immunomodulatory drugs. In
addition, there was potential for selection bias in that
younger and healthier patients may be selected to
undergo transplantation over an alternative treat-
ment. Hence, this study provided Class IV evidence
that for patients with POEMS syndrome, ASCT im-
proves neuropathy-related function.
ASCT universally improved neurologic symp-
toms, deficits, and necessity for gait aids in patients
with POEMS syndrome. The degree of neurologic
improvement was large and was sustained over the
length of the study. Although periengraftment syn-
drome was common, mortality remains much lower
than in patients treated with steroids and melphalan
only. Newer chemotherapeutic agents such as lenali-
domide are promising, and prospective randomized
clinical trials with comparison to ASCT would deter-
mine the best approach for patients with POEMS
syndrome.14 Such trials are difficult because of the
rarity of the disease. Until then, management is
mainly dictated by the overall performance status of
the patient, response to prior treatments, and experi-
ence with other similar conditions such as multiple
myeloma.
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and has partnered with Complete Practice Resources to provide you with an affordable online pro-
ject management tool to help walk you through each phase of the necessary preparation to ensure
you’re ready. Learn more at AAN.com/view/ICD10 and start your transition today!
Learn How to Become a Leader in Changing Health Care
Do you have ideas on how to improve health care? Learn to become an advocacy leader in your
clinic, institution, or community. Apply for the 2015 Palatucci Advocacy Leadership Forum. This
distinctive advocacy training program will be held January 15-18, 2015, at the Omni Amelia Island
Plantation Resort near Jacksonville, FL. Applications are due by September 21, 2014.
Graduates of the Palatucci Forum are successfully creating positive and lasting changes for their
patients and their profession across the globe. Many of today’s Academy leaders have participated
in this advocacy training and recommend it. For more information or to apply, visit AAN.com/view/
2015palf or contact Melissa Showers at mshowers@aan.com or (612) 928-6056.
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